ArticleJournal of applied clinical medical physics2026
Application of intrahepatic fiducial markers in carbon ion radiotherapy for pancreatic cancer-Achieving higher precision treatment.
Article in Journal of applied clinical medical physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Application of intrahepatic fiducial markers in carbon ion radiotherapy for pancreatic cancer-Achieving higher precision treatment.Journal of applied clinical medical physics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarbon-ion radiotherapy (CIRT) delivers highly conformal tumor doses while sparing surrounding organs-at-risk (OAR). However, density variations along the beam path and interfractional target motion can reduce target coverage and expose OAR to high doses. These motions are typically corrected using target matching (TM) or marker matching (MM). Because the pancreas is close to the gastrointestinal tract and major vessels, fiducial marker implantation carries a risk of organ or vascular injury, and metal artifacts from markers can affect beam range calculations. TM with computed tomography (CT) also reduces treatment efficiency and prevents real-time motion monitoring. PURPOSE: To improve pancreatic cancer CIRT by correcting interfractional target motion using fiducial markers implanted in hepatic segments 5 or 6.
methodsTwenty patients with implanted fiducial markers who underwent liver cancer CIRT at our hospital were selected. The effect of interfractional target motion correction by MM in pancreatic cancer CIRT was evaluated as simulation study. The initial planning CT and in-room CT images were used for bone matching (BM), liver-dome matching (LM), TM, and MM. Correlations between target motion and fiducial marker or liver-dome motion were analyzed, and fractional dose distributions were calculated. Variations in clinical target volume coverage (ΔCTV V95%) and OAR doses were examined across strategies per fraction.
resultsA strong correlation was observed between the motion of the target and the fiducial marker. The median ΔCTV V95% values were -4.68%, -3.97%, -1.07%, and -1.69% for BM, LM, TM, and MM, respectively. TM and MM significantly improved target coverage compared to BM and LM. OAR doses stayed within dose constraints for all methods.
conclusionThe proposed MM approach corrected interfractional target motion, achieving target coverage comparable to TM. In pancreatic cancer CIRT, managing gastrointestinal gas and body contour changes along with tumor motion may further optimize target coverage and improve clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.